Cocoa

Cocoa (Theobroma cacao L.): A Comprehensive Reference Article

1. Identity and Botanical Classification

1.1 Nomenclature and Taxonomy

Cocoa and cupuassu are evergreen Amazonian trees belonging to the genus Theobroma. In 1753, Linnaeus proposed the specific name Theobroma cacao, which remains to this day. The genus name Theobroma is derived from Greek, translating to "food of the gods" — a designation that reflects the plant's sacred status among pre-Columbian Mesoamerican civilizations. Cacao is a small evergreen tree in the family Malvaceae.

1.2 Botanical Origin and Cultivar Groups

Botanists believe that cocoa originates from the headwaters of the Amazon River, and it has expanded in two main directions, originating into two important groups: Criollo and Forastero. A third major hybrid group, Trinitario, also exists and combines traits of both lineages. The contents of flavan-3-ols, methylxanthines, and procyanidins can differ between cocoa beans according to their origin, genetics, and culture conditions.

1.3 Plant Parts Used and Common Forms

The seeds, commonly named cocoa beans, are used to make chocolate, cocoa butter, cocoa solids, and chocolate liquor. Following harvest, the beans undergo a sequence of fermentation, drying, roasting, and grinding to produce the commercial fractions used in food and supplement industries. Roasting reduces the amounts of total polyphenols, (−)-epicatechin, and proanthocyanidins in cocoa beans.

Principal commercial and supplement forms include:

• Raw/minimally processed cocoa powder: Ground, defatted cocoa with variable flavanol content depending on processing.
• Dutch-processed (alkalized) cocoa powder: Treated with alkali to reduce bitterness; alkalization substantially reduces flavanol content.
• Dark chocolate (≥70% cocoa): Retains a higher proportion of flavanols than milk chocolate.
• Cocoa butter: The fat fraction of the bean; used in cosmetics and food; flavanol-poor.
• Cocoa extracts / flavanol supplements: Standardized concentrated preparations used in clinical trials, such as the extract used in the COSMOS trial.

The amount of flavonols in cocoa decreases significantly during the chocolate manufacturing processes, and it also depends on where the cocoa comes from and the agricultural conditions in which it is grown.

---

2. Historical and Traditional Use

2.1 Olmec Civilization

The use of chocolate began in the New World with the ancient Olmec civilization (1500 BC–500 BC) in Mesoamerica and continued on through the time of the Maya and Aztecs before making its trek across to the Old World in the 16th century. The earliest evidence of the use of cacao in Mesoamerica dates back to 1900 BC in the Olmec civilization, but it was not until the Mayas and Aztecs that the use of cacao became widespread and deeply rooted in their culture.

2.2 Maya Civilization (c. 1000 BC – 900 CE)

The Mayans believed that cacao was a sacred food and used it in religious ceremonies and rituals. The Mayans (c. 1000 BC – 900 CE) used dozens of flavorings, from chillies to vanilla. The Maya ground the cocoa beans into a paste, which they then mixed with water and spices to create a bitter drink. There are records from the Mayan society, written in hieroglyphics, that reveal the significance of cacao in Mayan rituals; one of the records is presented in the "Popol Vuh," where it is mentioned that cacao is present in combination with godly rituals.

The Maya held a yearly festival to honor the cacao god Ek Chuah, which included several offerings and rituals to him. During funerals, cacao beans and vessels were buried with the deceased to accompany them into the afterlife.

2.3 Aztec/Mexica Civilization (c. 1300–1521 CE)

Evidence from codices shows that elaborate cacao recipes were produced by the Aztec people (1300–1521). Aztec/Mexica cultures prepared multiple drinks involving chocolate along with other ingredients such as chilli, vanilla, ceiba seed, hueinacaztli ("great ear" type of flower), mexcaxochitl ("String flower"), Magnolia mexicana, izquixochitl ("popcorn flower"), achiote, and black pepper.

Pre-Conquest chocolate was not a single concoction to be drunk; it was a vast and complex array of drinks, gruels, porridges, powders, and probably solid substances, to all of which a wide variety of flavorings could be added. The warm, liquid form of the chocolate consumed was very different from today's hot cocoa, being laden with chili powder and other spices, making it a hot and sultry treat popular with royalty while lay people occasionally enjoyed its healing qualities.

2.4 Introduction to Europe and Early Medicinal Claims

Cocoa consumption began in America, and in the mid-sixteenth century it quickly spread to Europe; beyond being considered a pleasant habit due to its rich sweet lingering taste, chocolate was considered a good nutrient and even a medicine. The Spanish who moved into Mesoamerica were unfamiliar with the spicy flavors of the chocolate and determined that it would not be popular as it stood and would not be sent back home without proper adjustments like the elimination of many spices and the addition of sweetening ingredients. In early modern Europe, cocoa beverages were promoted by physicians as treatments for fatigue, wasting, fever, and as general tonics, though these claims lacked scientific evaluation by contemporary standards.

---

3. Key Constituents and Active Compounds

3.1 Polyphenolic Compounds

Cocoa is a natural source of polyphenols, containing approximately 12–18% on a dry weight basis, which are organized into three groups: flavan-3-ols (catechins and epicatechins), anthocyanins, and procyanidins; representing approximately 37, 4, and 58%, respectively, of the total antioxidants in raw unfermented cocoa beans.

(-)-Epicatechin is the most abundant monomeric flavanol in cocoa powder. The single units (catechins) combine to form oligomers and polymers; the longer-chain oligomeric forms are the procyanidins. Cocoa is rich in procyanidins, theobromine, (-)-epicatechin, catechins, and caffeine.

3.2 Methylxanthines

Cocoa is also rich in methylxanthines, containing approximately 3.2% on a dry weight basis, such as theobromine and caffeine, which represent approximately 3.7% and 0.2% on a fat-free basis, respectively, and are considered central nervous system stimulants.

Theobromine, which is found in higher amounts than caffeine, seems to be behind several effects attributed to cocoa intake; its main mechanisms of action are inhibition of phosphodiesterases and blockade of adenosine receptors. In a study with volunteers to unravel the differential contributions of theobromine and caffeine on mood, psychomotor performance, and blood pressure, the authors concluded that caffeine might have more CNS-mediated effects on alertness, while theobromine might be acting primarily via peripheral physiological changes.

3.3 Other Nutritional Components

Nutritionally, cocoa contains biologically active substances that may affect human health: flavonoids (epicatechin and oligomeric procyanidins), theobromine, and magnesium. In addition to flavanols, cocoa contains about 380 known molecules, 10 of which are psychoactive compounds, such as methylxanthines (e.g., caffeine and theobromine).

3.4 Bioavailability

Theobromine and epicatechin are absorbed efficiently in the small intestine; oligomeric procyanidins are poorly absorbed in the small intestine, but catabolites are very efficiently absorbed after microbial biotransformation in the colon. Among the phytochemicals present in consumed cocoa, theobromine is most available in human plasma, followed by caffeine, (-)-epicatechin, catechin, and procyanidins.

---

4. Mechanisms of Action

4.1 Nitric Oxide Pathway and Vascular Effects

Flavanols found in cocoa have been shown to increase the formation of endothelial nitric oxide, which promotes vasodilation and therefore blood pressure reduction. Cocoa flavanols improve endothelial function via different pathways: they increase nitric oxide (NO) availability, stimulating eNOS function, preventing L-NAME-induced hypertension, and reducing reactive oxygen species (ROS); they also stimulate EDHF-mediated relaxation, inhibit endothelin-1, and reduce ACE activity.

4.2 Antioxidant and Anti-inflammatory Activity

The antioxidant properties of cocoa polyphenols may be responsible for many of their pharmacological effects, including the inhibition of lipid peroxidation and the protection of LDL-cholesterol against oxidation, and increase resistance to oxidative stress. The inhibition of human 5-LOX by cocoa flavonoids suggests that these compounds exert antileukotriene actions, which may confer a degree of anti-inflammatory, vasoprotective, and antibronchoconstrictory capacity.

4.3 Platelet Aggregation

Cocoa flavanols are also able to inhibit platelet activation, adhesion, and aggregation, mechanisms that play a central role in the development of endothelial dysfunction and atherosclerosis. Activated platelets secrete a number of adhesion molecules, such as P-selectin and C40 ligand, release inflammatory mediators into the local microenvironment, stimulate the chemotaxis of leukocytes to the site of inflammation, and generate ROS, reducing NO bioavailability and contributing to endothelial dysfunction and thrombosis.

4.4 Insulin Signaling and Metabolic Effects

Hypothesized mechanisms that underlie potential associations between cocoa flavanols and a reduced risk of chronic diseases include improvements in the lipid profile, insulin sensitivity, and endothelial function, and the alleviation of systemic inflammation, thrombosis, and oxidation. A range of potential mechanisms through which cocoa might improve cardiovascular health have been suggested, including the activation of nitric oxide (NO) and antioxidant/anti-inflammatory effects.

4.5 Central Nervous System: Theobromine and Cognition

The enhancing effect of theobromine on the levels of acetylcholine-related enzymes, dopamine, and especially noradrenalin confirms its beneficial role on the "cognitive reserve" and, consequently, a possible reducing effect on the cognitive decline underlying aging and Alzheimer's disease. In 2015, in a study of patients with Alzheimer's disease, theobromine was found to be associated with a favorable Aβ profile in the cerebrospinal fluid.

---

5. Scientific Evidence by Health Area

5.1 Cardiovascular Health: Blood Pressure

Meta-analyses of 20 studies involving 856 mainly healthy participants revealed a statistically significant blood pressure-reducing effect of flavanol-rich cocoa products compared with control in short-term trials of 2–18 weeks duration: Mean difference SBP (95% CI): −2.77 (−4.72, −0.82) mmHg, p = 0.005, n = 20; mean difference DBP (95% CI): −2.20 (−3.46, −0.93) mmHg, p = 0.006, n = 19 available for DBP. Trials provided participants with 30–1080 mg of flavanols (mean = 545.5 mg) in 3.6–105 g of cocoa products per day in the active intervention group.

Flavan-3-ol-rich foods considerably reduce elevated blood pressure and improve endothelial function independent of blood pressure, supporting their use for cardiovascular prevention. Effects were larger with elevated and hypertensive baseline blood pressure or categorical hypertension (office: −5.9/−2.7 mmHg). The considerable heterogeneity of effect sizes (I²>50%) between studies was not explained by the investigated factors, limiting the strength of evidence to "moderate."

5.2 Cardiovascular Health: Endothelial Function

Cocoa flavanol (CF) intake improves endothelial function in patients with cardiovascular risk factors and disease. The Flaviola Health Study, a randomized, controlled, double-masked, parallel-group dietary intervention trial, enrolled 100 healthy, middle-aged (35–60 years) men and women: participants consumed either a CF-containing drink (450 mg) or a nutrient-matched CF-free control bi-daily for 1 month. At 1 month, CF increased flow-mediated dilation (FMD) over control by 1.2% (95% CI 1.0, 1.4%).

The European Food Safety Authority (EFSA) stated that cocoa flavanols help to preserve endothelium-dependent vasodilation in healthy populations, if taken in quantities exceeding 200 mg of cocoa flavanols daily.

Flow-mediated dilation (FMD) increased after acute (+2.0% [1.6, 2.3]) and repetitive (+1.7% [1.3, 2.2]) consumption, independent of blood pressure.

5.3 Cardiovascular Health: Long-Term Clinical Events (COSMOS Trial)

COSMOS is the first large-scale, randomized, double-blind, placebo-controlled trial testing the long-term effects of cocoa flavanol supplementation in the prevention of CVD and cancer. The COSMOS trial (clinicaltrials.gov #NCT02422745) tested a cocoa extract supplement (2 capsules/day containing 500 mg cocoa flavanols/day, including 80 mg (–)-epicatechin; supplied by Mars Edge) and a multivitamin supplement to prevent CVD and cancer in 21,442 US adults, including 12,666 women aged ≥65 years and 8,776 men aged ≥60 years who were free of myocardial infarction, stroke, and recently diagnosed cancer within the past 2 years.

During a median follow-up of 3.6 years, 410 participants taking cocoa extract and 456 taking placebo had confirmed total cardiovascular events (HR: 0.90; 95% CI: 0.78, 1.02; P = 0.11). For secondary endpoints, HRs were 0.73 (95% CI: 0.54, 0.98) for CVD death, 0.87 (95% CI: 0.66, 1.16) for MI, 0.91 (95% CI: 0.70, 1.17) for stroke, 0.95 (95% CI: 0.77, 1.17) for coronary revascularization, neutral for other individual cardiovascular endpoints, and 0.89 (95% CI: 0.77, 1.03) for all-cause mortality.

After a median of 3.6 years of treatment among older women and men with high compliance and minimal loss to follow-up, there was no statistically significant effect on the primary outcome of total cardiovascular events; however, cocoa flavanol supplementation significantly reduced CVD death by 27%. In per-protocol analyses, cocoa extract reduced the primary outcome of total cardiovascular events among those compliant with the active intervention, compared with those compliant with the placebo.

Evidence assessment: The COSMOS trial provides the most rigorous and large-scale evidence to date on hard clinical cardiovascular outcomes. The primary endpoint was not met, though secondary signals — particularly a 27% reduction in cardiovascular death — are clinically noteworthy. These findings are hypothesis-generating but require replication.

5.4 Lipid Profile and Metabolic Biomarkers

A systematic review and meta-analysis included 19 RCTs comprising 1,131 participants; the amount of cocoa flavanols ranged from 166 to 2,110 mg/day, and intervention duration ranged from 2 to 52 weeks; cocoa flavanol intake significantly improved insulin sensitivity and lipid profile.

The weighted mean differences between treatment and placebo were −0.10 mmol/L (95% CI: −0.16, −0.04 mmol/L) for total triglycerides, 0.06 mmol/L (95% CI: 0.02, 0.09 mmol/L) for HDL cholesterol, −2.33 μIU/mL (95% CI: −3.47, −1.19 μIU/mL) for fasting insulin, −0.93 (95% CI: −1.31, −0.55) for the homeostatic model assessment of insulin resistance (HOMA-IR), 0.03 (95% CI: 0.01, 0.05) for the quantitative insulin sensitivity check index, 2.54 (95% CI: 0.63, 4.44) for the insulin sensitivity index, −0.83 mg/dL (95% CI: −0.88, −0.77 mg/dL) for C-reactive protein, and 85.6 ng/mL (95% CI: 16.0, 155 ng/mL) for vascular cell adhesion molecule 1.

A separate meta-analysis in patients with type 2 diabetes found that cocoa products intake had beneficial long-term effects on cardiometabolic biomarkers for type 2 diabetes, especially on blood glucose, lipid metabolism (LDL-C and TG), and inflammation (CRP). Specifically, cocoa products significantly decreased LDL-cholesterol (WMD: −9.955 mg/dL, 95% CI: −17.408, −2.501, p = 0.009) and triglycerides (WMD: −15.364 mg/dL, 95% CI: −23.383, −7.346, p < 0.001).

Evidence assessment: Short-to-medium-term RCT evidence in this area is moderately strong for specific biomarkers (HDL, triglycerides, HOMA-IR, CRP). Effect sizes are modest. Generalizability is limited by study heterogeneity and variable flavanol content across products. Effect sizes were small to moderate for most biomarkers; therefore, findings for those biomarkers need to be confirmed by further investigations and interpreted with caution.

5.5 Cognitive Function

In 2012, Desideri et al., in a parallel double-blind trial (CoCoA study), tested whether dietary flavanols might improve cognitive function in subjects with mild cognitive impairment (MCI); neuropsychological function was assessed in 90 older persons with a mean age of 71 years, randomized to consume a high-flavanol (990 mg/day) or an intermediate (520 mg/day) drink, for 8 weeks. At the end of the follow-up period, in the high- and intermediate flavanol compared to the low-flavanol groups, the times required to complete both trail making tests (TMT) A and B were significantly lower; the verbal fluency score was significantly better; the high- and intermediate flavanol groups also exhibited decreased insulin resistance, blood pressure, and lipid peroxidation.

The parallel-arm, double-blind CoCoA (Cocoa, Cognition, and Aging) trial included 90 older adults with amnestic mild cognitive impairment (aMCI) and 90 older adults with cognitively normal (CN) status who received a daily drink containing low (45 mg/day), medium (520 mg/day), or high (993 mg/day) amounts of cocoa flavanols over 8 weeks. Regardless of baseline cognitive status (aMCI or CN), randomization to both high- and medium-cocoa flavanol intake groups, compared with the low-intake group, showed significant benefits on an overall cognition composite score that included the 3MS, TMT-A, TMT-B, and verbal fluency tests.

The COSMOS-Mind sub-trial tested cognition in a large, longer-term setting. COSMOS-Mind, a large randomized two-by-two factorial 3-year trial, assessed cognition by telephone at baseline and annually. COSMOS-Mind tested whether daily administration of cocoa extract (containing 500 mg/day flavanols) improved cognitive outcomes. Over 3 years, 110 incident MCI and 14 incident dementia cases were adjudicated; incidence rates did not vary by assignment to multivitamin-mineral or cocoa extract (all p ≥ 0.05), however statistical power was low.

Evidence assessment: Short-term (8-week) RCT data from the CoCoA trials in older adults show promising signals for cognitive improvement, particularly in individuals with MCI or lower habitual flavanol intake. The larger COSMOS-Mind trial, conducted over 3 years but using telephone-based assessments, did not demonstrate a statistically significant effect on incident MCI or dementia with low statistical power. Evidence remains preliminary to moderate for cognition; longer-term in-person RCTs are needed.

5.6 Anti-inflammatory and Antioxidant Effects

The phenolics from cocoa modify the glycemic response and the lipid profile, decrease platelet function and inflammation along with diastolic and systolic arterial pressures, which, taken together, may reduce the risk of cardiovascular mortality. Clinical studies have documented reductions in C-reactive protein and VCAM-1 in flavanol intervention groups (see Section 5.4 for specific values). These effects are considered mechanistically plausible and supported by RCT data, though effect sizes for inflammation markers are modest.

5.7 Mood and Psychomotor Performance

Theobromine and caffeine, in the proportions found in cocoa, are responsible for the liking of the food/beverage; these compounds influence in a positive way our moods and our state of alertness. A randomized, placebo-controlled, double-blind clinical trial (n = 40, mean age = 24.13 years) was conducted to investigate the effects of both acute (same-day) and sub-chronic (daily for four weeks) 250 mg cocoa supplementation on mood and mental fatigue, cognitive performance, and cardiovascular functioning in young, healthy adults. Evidence for consistent mood benefits from cocoa is preliminary; study populations, doses, and endpoints are heterogeneous, and effect sizes in healthy younger adults have not been uniformly robust.

5.8 Cardiometabolic Risk Markers: Overall Evidence Summary

Intervention studies strongly suggest that cocoa exerts a beneficial impact on cardiovascular health, through the reduction of blood pressure, improvement of vascular function, modulation of lipid and glucose metabolism, and reduction of platelet aggregation; these potentially beneficial effects have been shown in healthy subjects as well as in patients with risk factors (arterial hypertension, diabetes, and smoking) or established CVD (coronary heart disease or heart failure). However, the impact of cocoa consumption in reducing cardiometabolic risk markers has yet to be established, since the results from randomized clinical trials are controversial; in addition, the amount, frequency, and form of both cocoa and polyphenol intake that could provide these benefits has not been established.

---

6. Dosage Forms and Dosages Reported in Studies

The following dosages are reported directly from cited clinical studies and should not be interpreted as therapeutic recommendations:

• Endothelial function (EFSA opinion): The EFSA stated that cocoa flavanols help to preserve endothelium-dependent vasodilation in healthy populations if taken in quantities exceeding 200 mg cocoa flavanols daily.
• Blood pressure meta-analysis (short-term trials): Trials provided participants with 30–1,080 mg of flavanols (mean = 545.5 mg) in 3.6–105 g of cocoa products per day. In half of the trials, the active group consumed 500–750 mg of flavanols per day.
• Flaviola Health Study (endothelial function, healthy adults, 1 month): 100 healthy, middle-aged (35–60 years) men and women consumed either a CF-containing drink (450 mg) or a nutrient-matched CF-free control bi-daily for 1 month.
• CoCoA Study (cognition, older adults with MCI, 8 weeks): Participants received a daily drink containing low (45 mg/day), medium (520 mg/day), or high (993 mg/day) amounts of cocoa flavanols over 8 weeks.
• COSMOS Trial (cardiovascular events and cognition, median 3.6 years): Participants were randomly assigned to a cocoa extract supplement containing 500 mg flavanols/day, including 80 mg (–)-epicatechin, or placebo.
• Systematic review range (biomarkers): The amount of cocoa flavanols ranged from 166 to 2,110 mg/day, and intervention duration ranged from 2 to 52 weeks.
• Sub-chronic supplementation (young adults, mood/cognition, 4 weeks): A randomized, placebo-controlled, double-blind clinical trial investigated the effects of both acute (same-day) and sub-chronic (daily for four weeks) 250 mg cocoa supplementation.

Pilot trials of up to 100 participants with 4–12 weeks of varying doses of cocoa flavanols in different patient groups provide consistent evidence for cardiovascular benefits at doses >700 mg/day and without adverse events.

---

7. Safety Considerations and Interactions

7.1 General Tolerability

Reported adverse events in flavanol intervention trials were minor and low (0.4%). These promising interventions have both already shown favorable results in prior research studies, and are well-tolerated and safe in trial settings.

7.2 Caffeine and Theobromine-Related Effects

Eating large amounts might cause caffeine-related side effects such as nervousness, increased urination, sleeplessness, and a fast heartbeat. Some studies reported symptoms like nausea, vomiting, headache, and diarrhea after consuming theobromine-rich cocoa. Unlike what happens in other mammals — including pets — theobromine is safe for humans and has fewer unwanted effects than caffeine.

The combination of caffeine and theobromine in cocoa may have the expected methylxanthine-derived benefits without the side effects reported for caffeine. Cocoa extract also contains methylxanthines such as theobromine and caffeine, which may enhance the vascular and central nervous system effects of cocoa flavanols.

7.3 Heavy Metal Contamination

Cocoa products have the potential of contamination with heavy metals (i.e., lead, cadmium), either from growth in contaminated soil or from contamination during the manufacturing processes. An analysis of 72 consumer cocoa-containing products purchased between 2014 and 2022 found that 43%, 35%, and 0% of the products tested exceeded California Proposition 65 maximum allowable dose levels for lead, cadmium, and arsenic, respectively, while 97.2% (70 of 72) fell below US FDA interim reference levels for lead.

This indicates that heavy metal contamination in more than half of products tested may not pose any appreciable risk for the average person when consumed as a single serving; however, consuming some of the products tested, or more than one serving per day in combination with non-cocoa-derived sources of heavy metals, may add up to exposure that would exceed the Prop 65 maximum allowable dose levels. Notably, "organic" products were significantly more likely to demonstrate higher levels of both cadmium and lead.

Dark chocolate products, which contain high amounts of cocoa, can contain high levels of lead and cadmium, which can cause serious health issues in children.

7.4 Pregnancy and Breastfeeding

Cocoa products should be consumed in moderation during pregnancy and breastfeeding. Consuming cocoa in larger amounts is possibly unsafe because of the caffeine and heavy metals it contains. Breast milk concentrations of caffeine are thought to be about half the level of caffeine in the breastfeeding parent; if too much chocolate (16 oz per day) is consumed when breastfeeding, the nursing infant may become irritable and have frequent bowel movements because of the caffeine.

7.5 Allergic Reactions and Migraine

Cocoa can cause allergic skin reactions and might also trigger migraine headaches. These effects are considered uncommon in the general population and have not been systematically quantified in large-scale RCTs.

7.6 Flavanol Content Variability and Processing

The amount of flavonols in cocoa decreases significantly during the chocolate manufacturing processes, and it also depends on where the cocoa comes from and the agricultural conditions in which it is grown. Roasting reduces the amounts of total polyphenols, (−)-epicatechin, and proanthocyanidins in cocoa beans. Dutch-processing (alkalization) is associated with further reductions. This means that stated flavanol doses in product labels may not accurately reflect actual flavanol content, complicating translation of research findings to consumer products.

---

References

• ScienceDirect Topics: Theobroma Cacao — Overview
• Jean-Marie E. et al. (2022). Theobroma cacao and Theobroma grandiflorum: Botany, Composition and Pharmacological Activities of Pods and Seeds. Foods, 11(24), 3966. MDPI.
• Cocoa extract with high content of flavan 3-ols, procyanidins and methylxanthines — PMC
• Rusconi M, Conti A. (2013). Theobroma cacao L., the food of the gods: A scientific approach. PubMed — Cocoa and human health.
• Martínez-Pinilla E. et al. (2015). Cocoa phytochemicals: recent advances in molecular mechanisms on health. PubMed.
• From Cocoa to Chocolate: Effect of Processing on Flavanols and Methylxanthines and Their Mechanisms of Action — PMC
• Ried K. et al. (2012). Effect of cocoa on blood pressure. Cochrane Database / PubMed.
• Sansone R. et al. (2015). Cocoa flavanol intake improves endothelial function and Framingham Risk Score in healthy men and women: the Flaviola Health Study. British Journal of Nutrition. PMC.
• Ludovici V. et al. (2017). Cocoa, Blood Pressure, and Vascular Function. PubMed.
• Ludovici V. et al. (2017). Cocoa, Blood Pressure, and Vascular Function. Frontiers in Nutrition.
• Heiss C. et al. (2025). Impact of flavan-3-ols on blood pressure and endothelial function: a systematic review and meta-analysis of RCTs. PubMed.
• Acute Effects of Cocoa Flavanols on Blood Pressure and Peripheral Vascular Reactivity in Type 2 Diabetes Mellitus and Essential Hypertension — PMC (EFSA reference)
• Sesso HD, Manson JE et al. (2022). Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COSMOS randomized clinical trial. American Journal of Clinical Nutrition. PMC.
• Ried K. et al. (2016). Cocoa Flavanol Intake and Biomarkers for Cardiometabolic Health: A Systematic Review and Meta-Analysis of RCTs. PMC.
• Effects of Cocoa Consumption on Cardiometabolic Risk Markers: Meta-Analysis of RCTs. (2024). Nutrients. MDPI.
• Chen X. et al. (2021). Effects of cocoa products intake on cardiometabolic biomarkers of type 2 diabetes patients: a systematic review and meta-analysis. PubMed.
• Desideri G. et al. (2012). Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: the CoCoA Study. PMC.
• Chocolate and Cocoa-Derived Biomolecules for Brain Cognition during Ageing — PMC (2022).
• Baker LD, Manson JE et al. (2023). Effects of cocoa extract and a multivitamin on cognitive function: A randomized clinical trial. Alzheimer's & Dementia.
• Sachs BC et al. (2023). Impact of multivitamin-mineral and cocoa extract on incidence of mild cognitive impairment and dementia: COSMOS-Mind. PMC.
• Effect of cocoa extract supplementation on cognitive function: results from the clinic subcohort of the COSMOS trial — PMC.
• Massee LA et al. (2015). The acute and sub-chronic effects of cocoa flavanols on mood, cognitive and cardiovascular health in young healthy adults: a randomized, controlled trial. PMC.
• Arranz S. et al. (2012). Cocoa Polyphenols and Their Potential Benefits for Human Health — PMC.
• The action of phytochemicals present in cocoa in the prevention of vascular dysfunction and atherosclerosis — PMC (2022).
• Martínez-Pinilla E. et al. (2015). The relevance of theobromine for the beneficial effects of cocoa consumption. Frontiers in Pharmacology. PMC.
• A multi-year heavy metal analysis of 72 dark chocolate and cocoa products in the USA — PMC (2024).
• Examine.com: Cocoa Extract — Research Breakdown and Safety.
• HeritagaDaily: Medicinal and Ritualistic Uses for Chocolate in Mesoamerica.
• EarthStoriez: The Curative Use of Cocoa in Mesoamerican History and Heritage.
• EFSA (2011). Scientific Opinion on the substantiation of health claims related to cocoa flavanols and enhancement of mood and endothelial function. EFSA Journal.